Table 3.
Precedent medical events during the 6 weeks before the onset of Guillain-Barré syndrome.
| Category | Overall (July 2014–June 2016) n = 533 |
2014–2015 Season (July 2014–June 2015) n = 262 |
2015–2016 Season (July 2015–June 2016) n = 271 |
||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Any infection/surgery/influenza vaccine | 312 | 58.54 | 154 | 58.78 | 158 | 58.30 | |
| Anatomical infection site | Upper respiratory | 225 | 42.21 | 110 | 41.98 | 115 | 42.44 |
| Lower respiratory | 1 | 0.19 | 0 | 0.00 | 1 | 0.37 | |
| Gastro-intestinal | 65 | 12.20 | 31 | 11.83 | 34 | 12.55 | |
| Pathogen | Malaria | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Tsutsugamushi | 3 | 0.56 | 0 | 0.00 | 3 | 1.11 | |
| Campylobacter | 1 | 0.19 | 1 | 0.38 | 0 | 0.00 | |
| Cytomegalovirus | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Epstein-Barr virus | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Herpes simplex virus | 5 | 0.94 | 3 | 1.15 | 2 | 0.74 | |
| Varicella (Chickenpox) | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Herpes zoster virus | 12 | 2.25 | 4 | 1.53 | 8 | 2.95 | |
| Mycoplasma | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Hemophilus influenzae | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Influenza virus | 51 | 9.57 | 26 | 9.92 | 25 | 9.23 | |
| Parainfluenza virus | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Other viruses | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Other infections | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Surgery | 44 | 8.26 | 23 | 8.78 | 21 | 7.72 | |
| Influenza vaccine (trivalent) * | 32 | 5.82 | 13 | 4.96 | 19 | 7.01 | |
* All influenza vaccines to be studied are trivalent vaccines, and the compositions of the vaccines are as follows: In the 2014–2015 season: An A/California/7/2009 (H1N1)pdm09-like virus; an A/Texas/50/2012 (H3N2)-like virus; and a B/Massachusetts/2/2012-like virus. In the 2015–2016 season: An A/California/7/2009 (H1N1)pdm09-like virus; an A/Switzerland/9715293/2013 (H3N2)-like virus; and a B/Phuket/3073/2013-like virus [5].